Clinical development failure
Product candidates may not show sufficient safety or efficacy in trials.
- Scope
- SL-325 and other immune-mediated disease programs
- Materiality
- high
Shattuck Labs, Inc.
Shattuck Labs is a U.S.-based clinical-stage biotechnology company focused on discovering and developing antibody-based therapies for immune-mediated diseases. The company’s pipeline has centered on programs such as SL-325 and earlier candidates, with research, development, and clinical operations conducted from its U.S. offices in Austin, Texas and Durham, North Carolina.
−4 780,8 %
−4 880,9 %
−82,5 %
11.70
11.70
| % | |
|---|---|
| Clinical-stage drug candidates | 70% Antibody-based therapeutic programs being advanced through preclinical and clinical development. |
| Collaboration and license revenue | 20% Revenue from research, licensing, and collaboration agreements with third parties. |
| Discovery and translational research | 10% Internal research activities that generate new therapeutic candidates and platform insights. |
Shattuck Labs does not sell approved commercial products; its economic counterparties are pharmaceutical and...
- Pharmaceutical and biotechnology collaboratorsprimary
Partners that enter research, option, or license agreements around Shattuck’s antibody programs and platform assets.
- Clinical development partnerssecondary
Organizations that may support or co-develop later-stage trials, manufacturing, or commercialization.
- Patients with immune-mediated diseasesprimary
The eventual end users of approved therapies targeting inflammatory and immune-mediated conditions.
Shattuck Labs is headquartered and operates in the United States, with corporate offices in Austin, Texas and Durham,...
- •Headquartered in the United States
- •Corporate offices in Austin, Texas and Durham, North Carolina
- •U.S.-based employees and research operations
- •Clinical trials and manufacturing are outsourced to third parties
- •No disclosed country-level revenue concentration
The company’s strategy is to advance antibody programs for immune-mediated diseases, with emphasis on clinical...
01
Advance SL-325 into later-stage developmentshort-term
Clinical progress is the main value driver for a company without commercial products.
02
Strengthen internal development capabilitiesmedium-term
More in-house expertise can improve execution in research, process development, and clinical operations.
03
Use partnerships to extend capital runway and broaden reachmedium-term
Collaborations can provide non-dilutive funding and external validation of the platform.
Shattuck Labs faces the typical risks of a clinical-stage biotech company: uncertain trial outcomes, regulatory...
Capital dependence
The company has no commercial product revenue and must fund long development cycles.
- Scope
- Operating runway and trial funding
- Materiality
- high
Third-party manufacturing and trial execution
CROs and contract manufacturers control key parts of development and supply.
- Scope
- Clinical timelines, quality, and material availability
- Materiality
- high
Intellectual property protection
Patent coverage is needed to protect candidate molecules, methods, and formulations.
- Scope
- Platform technology and lead programs
- Materiality
- high
Competitive pressure
Larger companies and other clinical-stage peers are pursuing similar immune targets.
- Scope
- TL1A/DR3-axis and broader immune-mediated disease space
- Materiality
- medium
Revenue recognition for collaboration agreements
Affects reported quarterly and annual revenue
Accrued research and development expenses
Affects operating expenses and liabilities
Stock-based compensation
Affects operating expense and dilution analysis
: 29.4.2026